Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Common Equity (2016 - 2025)

Historic Common Equity for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $176.3 million.

  • Angiodynamics' Common Equity fell 558.71% to $176.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $176.3 million, marking a year-over-year decrease of 558.71%. This contributed to the annual value of $183.0 million for FY2025, which is 1100.07% down from last year.
  • Per Angiodynamics' latest filing, its Common Equity stood at $176.3 million for Q4 2025, which was down 558.71% from $178.9 million recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' Common Equity peaked at $454.9 million during Q1 2021, and registered a low of $176.3 million during Q4 2025.
  • Over the past 5 years, Angiodynamics' median Common Equity value was $399.4 million (recorded in 2023), while the average stood at $328.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 332.41% in 2023, then plummeted by 5404.86% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Common Equity stood at $432.4 million in 2021, then fell by 5.65% to $408.0 million in 2022, then decreased by 1.65% to $401.2 million in 2023, then tumbled by 53.45% to $186.8 million in 2024, then fell by 5.59% to $176.3 million in 2025.
  • Its Common Equity stands at $176.3 million for Q4 2025, versus $178.9 million for Q3 2025 and $183.0 million for Q2 2025.